Early urinary CCL2 is associated with the later development of interstitial fibrosis and tubular atrophy in renal allografts

Transplantation

Volumn 90, Issue 4, 2010, Pages 394-400

  Ho, Julie ^a,b   Rush, David N ^a   Gibson, Ian W ^a   Karpinski, Martin ^a   Storsley, Leroy ^a   Bestland, Jennifer ^b   Stefura, William ^a   Hayglass, Kent T ^a   Nickerson, Peter W ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Chemokines; Chronic allograft nephropathy; Monocyte chemoattractant protein 1 (CCL2); Urinary biomarker

Indexed keywords

ALPHA 1 MICROGLOBULIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CXCL9 CHEMOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ARTICLE; ATROPHY; CONCENTRATION (PARAMETERS); DELAYED GRAFT FUNCTION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT DYSFUNCTION; HUMAN; HUMAN TISSUE; INTERSTITIAL FIBROSIS AND TUBULAR ATROPHY; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEPHELOMETRY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; RISK FACTOR; UNIVARIATE ANALYSIS; URINALYSIS;

EID: 77955981759     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181e6424d     Document Type: Article

References (42)

1. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural historyof chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
2. Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307.
3. Chapman JR. Longitudinal analysis of chronic allograft nephropathy: Clinicopathologic correlations. Kidney Int 2005; 99: S108.
4. Pascual M, Theruvath T, Kawai T, et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580.
5. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: Current concepts and future directions. Transplantation 2006; 81: 643.
6. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527.
7. Cosio FG, Grande JP, Larson TS, et al. Kidney allograft fibrosis and atrophy early after living donor transplantation. Am J Transplant 2005; 5: 1130.
8. Nicholson ML, McCullouch TA, Harper SJ, et al. Early measurement of interstitial fibrosis predicts long-term renal function and graft survival in renal transplantation. Br J Surg 1996; 83: 1082.
9. Nicholson ML, Bailey E, Williams S, et al. Computerized histomor-phometric assessment of protocol renal transplant biopsy specimens for surrogate markers of chronic rejection. Transplantation 1999; 68: 236.
10. Seron D, Moreso F, Bover J, et al. Early protocol renal allograft biopsies and graft outcome. Kidney Int 1997; 51: 310.
11. Nickerson P, Jeffrey J, Gough J, et al. Identification of clinical and histopathologic risk factors for diminished renal function 2 years post-transplant. J Am Soc Nephrol 1998; 9: 482.
12. Grimm PC, Nickerson P, Gough J, et al. Computerized image analysis of Sirius red-stained renal allograft biopsies as a surrogate marker to predict long-term allograft function. J Am Soc Nephrol 2003; 14: 1662.
13. Sund S, Grimm P, Reisaeter AV, et al. Computerized image analysis vs semi-quantitative scoring in evaluation of kidney allograft fibrosis and prognosis. Nephrol Dial Transplant 2004; 19: 2838.
14. Moreso F, Ibernon M, Gomà M, et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006; 6: 747.
15. Ho J, Lucy M, Krokhin O, et al. Mass spectrometry-based proteomic analysis of urine in acute kidney injury following cardiopulmonary bypass: A nested case-control study. Am J Kidney Dis 2009; 53: 584.
16. Schaub S, Nickerson P, Rush D, et al. Urinary CXCL9 and CXCL10 levels correlate with extent of subclinical tubulitis. Am J Transplant 2009; 9: 1347.
17. Hu H, Aizenstein BD, Puchalski A, et al. Elevation of CXCR3-binding chemokines in urine indicates acute renal allograft dysfunction. Am J Transplant 2004; 4: 432.
18. Hauser IA, Spiegler S, Kiss E, et al. Prediction of acute renal allograft rejection by urinary monokine induced IFN-{gamma} (Mig). J Am Soc Nephrol 2005; 16: 1849.
19. Matz M, Beyer J, Wunsch D, et al. Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short-and long term graft function. Kidney Int 2006; 69: 1683.
20. Rush D, Nickerson P, Gough J, et al. Beneficial effects of treatment of early subclinical rejection: A randomized study. J Am Soc Nephrol 1998; 9: 2129.
21. Rush D, Arlen D, Boucher A, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: A randomized study. Am J Transplant 2007; 7: 2538.
22. Rush DN, Cockfield SM, Nickerson PW, et al. Factors associated with progression of interstitial fibrosis in renal transplant patients receiving tacrolimus and mycophenolate mofetil. Transplantation 2009; 88: 897.
23. GangurV, Simons FE, Hayglass KT. Human IP-10 selectively promotes dominance of polyclonally activated and environmental antigen-driven IFN-gamma over IL-4 responses. FASEB J 1998; 12: 705.
24. Carr MW, Roth SJ, Luther E, et al. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Nat Acad Sci\USA 1994; 91: 3652.
25. Allavena P, Bianchi G, Zhou D, et al. Induction of natural killer cell migration by monocyte chemoattractant protein-1,-2, and-3. Eur J Immunol 1994; 24: 3233.
26. Wang T, Dai H, Wan N, et al. The role for monocyte chemoattractant protein-1 in the generation and function of memory CD8 T cells. J Immunol 2008; 180: 2886.
27. Ogliari AC, Caldara R, Socci C, et al. High levels of donor CCL2/MCP1 predict graft-related complications and poor graft survival after kidney-pancreas transplantation. Am J Transplant 2008; 8: 1303.
28. Hu H, Kwun J, Aizenstein BD, et al. Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine. Transplantation 2009; 87: 1814.
29. Dubinksi B, Boratynska M, Kopec W, et al. Activated cells in urine and monocyte chemotactic peptide-1 (MCP-1)\Sensitive rejection markers in renal graft recipients. Transpl Immunol 2008; 18: 203.
30. Prodjosudjadi W, Daha MR, Gerritsma JS, et al. Increased urinary excretion of monocyte chemoattractant protein-1 during acute renal al-lograft rejection. Nephrol Dial Transplant 1996; 11: 1096.
31. Lehmann I, Fischereder M, Bohmig GA, et al. The source matters: No impact of the CCL2/MCP-1-2518G polymorphism of the donor on renal allograft outcome during the first year after transplantation. Transplant Proc 2008; 40: 3359.
32. Kruger B, Schroppel B, Ashkan R, et al. A monocyte chemoattractant protein-1 (MCP-1) polymorphism and outcome after renal transplantation. J Am Soc Nephrol 2002; 13: 2585.
33. Kang SW, Park SJ, Kim YW, et al. Association of MCP-1 and CCR2 polymorphisms with the risk of late acute rejection after renal transplantation in Korean patients. Int J Immunogenet 2008; 35: 25.
34. Zheng G, Wang Y, Xiang SH, et al. DNA vaccination with CCL2 DNA modified by the addition of an adjuvant epitope protects against "non-immune" toxic renal injury. J Am Soc Nephrol 2006; 17: 465.
35. Wada T, Furuichi K, Sakai N, et al. Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J Am Soc Nephrol 2004; 15: 940.
36. Kitigawa K, Wada T, Furuichi K, et al. Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am J Pathol 2004; 165: 237.
37. Klein J, Gonzalez J, Duchene J, et al. Delayed blockade of the kinin B1 receptor reduces renal inflammation and fibrosis in obstructive urop-athy. FASEB J 2009; 23: 134.
38. Wang PH, Cenedeze MA, Campanolle G, et al. Deletion of bradykinin B1 receptor reduces renal fibrosis. Int Immunopharm 2009; 9: 653.
39. Li C, Yang CW. The pathogenesis and treatment of chronic allograft nephropathy. Nat Rev Nephrol 2009; 5: 513.
40. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137.
41. Solez K, Colvin RB, Racusen LC, et al. Banff 07 Classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753.
42. Stefura WP, Campbell JD, Douville R, et al. Ultrasensitive ELISA for measurement of human cytokine responses in primary culture. Methods Mol Med 2008; 138: 107.